Samsung Bioepis acquires domestic product approval of ‘Renflexis’

Published: 2015-12-09 13:49:08

Updated: 2015-12-09 13:49:08

Samsung Bioepis announced acquisition of product approval of Renflexis(Remicade biosimilar), an autoimmune disease treatment, from the Ministry of Food and Drug Safety on the 4^th.

Thus, Samsung Bioepis has become a company owning two autoimmune disease treating biosimilars along with Brenzys approved this Septemer.

CEO Han-seung Goh of Samsung Bioepis stated, “We were able to acquire domestic...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.